$80K — $100K *
IGM (Nasdaq: IGMS) is a biotechnology company pioneering the development of engineered IgM antibodies for the treatment of cancer patients. IgM antibodies have inherent properties that we believe may enable them to improve upon the efficacy and safety of IgG antibodies in multiple therapeutic applications.
We have created a proprietary IgM antibody technology platform that we believe is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. Our lead product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3, that is currently in a Phase 1 clinical trial for the treatment of relapsed/refractory B cell Non-Hodgkin’s lymphoma (NHL). Our second product candidate is IGM-8444, an IgM antibody targeting Death Receptor 5 (DR5) for the treatment of patients with solid and hematologic malignancies. Also in our product pipeline is IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.
We are seeking a talented and motivated Scientist or Senior Scientist to join the Protein Sciences team. As part of our Antibody Discovery department you’ll support research and pre-clinical therapeutic programs. The ideal candidate will have deep experience in protein production, particularly in the context of antibody and antibody-like biologics, and a solid background in protein purification and bioanalytical techniques used to characterize biologics. In this key position you will participate on cross-functional teams in a dynamic, fast-paced and collaborative environment, focused on progressing innovative therapeutic antibody programs. This position reports to the Director, Protein Sciences.
Valid through: 8/27/2020